# Advancements and Challenges in Tissue-Engineered Heart Valves: Integrating Biomechanics, Biomaterials, and Biomimetic Design for Functional Maturity

**Authors:** Lorenzo Guidi, Elisabetta Rosellini, Gaia Riccio, Maria Grazia Cascone

PMC · DOI: 10.3390/biomimetics11030185 · Biomimetics · 2026-03-04

## TL;DR

This review explores how to build better heart valve replacements by mimicking natural valve structures and functions.

## Contribution

The paper introduces biomimetic design principles that integrate biomechanics, materials, and cell behavior to improve tissue-engineered heart valves.

## Key findings

- Biomimetic scaffolds can replicate native valve extracellular matrix organization and nonlinear mechanics.
- Dynamic bioreactors help mature engineered valves through mechanical stimulation.
- Immune modulation and scaffold anisotropy are critical for successful clinical translation.

## Abstract

Valvular heart disease remains a major global health burden, with currently available prosthetic heart valves failing to fully reproduce the adaptive, regenerative, and long-term functional properties of native valves. Tissue-engineered heart valves (TEHVs) have emerged as a promising alternative, aiming to develop living valve replacements capable of growth, remodeling, and physiological integration. However, despite substantial progress, the clinical translation of TEHVs remains limited, indicating the need for design strategies that go beyond material selection toward functionally mature constructs. This review presents recent advances in TEHV development from a biomimetic perspective, using native heart valves as a biological reference characterized by hierarchical structure, anisotropic mechanical behavior, mechanoresponsive cell populations, immune regulation, and temporally coordinated remodeling. We integrate current understanding of valve biology and mechanobiology with advances in scaffold materials and architecture, bioactive functionalization, biomechanical conditioning, and emerging fabrication and monitoring technologies. We discuss how biomimetic scaffold designs aim to replicate native extracellular matrix organization and nonlinear mechanics, how biological cues are used to regulate thrombosis, immune response, and cell recruitment, and how dynamic bioreactor systems support functional tissue maturation through controlled mechanical stimulation. Finally, key challenges for clinical translation are highlighted, and future directions are outlined, emphasizing integrated and biomimetically informed design approaches. Overall, this review aims to define guiding principles that may accelerate the development of durable, regenerative, and clinically translatable tissue-engineered heart valves. We argue that successful TEHV translation requires synchronized control of scaffold anisotropy, immune modulation, and mechanical conditioning rather than incremental material optimization.

## Full-text entities

- **Genes:** CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, Vim (vimentin) [NCBI Gene 81818], FGF2 (fibroblast growth factor 2) [NCBI Gene 2247] {aka BFGF, FGF-2, FGFB, HBGF-2}, CDH5 (cadherin 5) [NCBI Gene 1003] {aka 7B4, CD144}, Acan (aggrecan) [NCBI Gene 58968] {aka Agc, Agc1}, ELN (elastin) [NCBI Gene 2006] {aka ADCL1, SVAS, WBS, WS}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, NPPC (natriuretic peptide C) [NCBI Gene 4880] {aka CNP, CNP2}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, F2 (coagulation factor II, thrombin) [NCBI Gene 2147] {aka PT, RPRGL2, THPH1}, VCAN (versican) [NCBI Gene 1462] {aka CSPG2, ERVR, GHAP, PG-M, WGN, WGN1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, CNP (2',3'-cyclic nucleotide 3' phosphodiesterase) [NCBI Gene 1267] {aka CN37, CNP1, HLD20}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, PROM1 (prominin 1) [NCBI Gene 8842] {aka AC133, CD133, CORD12, MCDR2, MSTP061, PROML1}, Acta2 (actin alpha 2, smooth muscle) [NCBI Gene 81633], GDF11 (growth differentiation factor 11) [NCBI Gene 10220] {aka BMP-11, BMP11, VHO}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, PTEN (phosphatase and tensin homolog) [NCBI Gene 5728] {aka 10q23del, BZS, CWS1, DEC, GLM2, MHAM}, ARG1 (arginase 1) [NCBI Gene 383], NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, RUNX2 (RUNX family transcription factor 2) [NCBI Gene 860] {aka AML3, CBF-alpha-1, CBFA1, CCD, CCD1, CLCD}, CD34 (CD34 molecule) [NCBI Gene 947], PLG (plasminogen) [NCBI Gene 5340] {aka HAE4}, Ccl2 (C-C motif chemokine ligand 2) [NCBI Gene 20296] {aka HC11, JE, MCAF, MCP-1, MCP1, SMC-CF}
- **Diseases:** platelet aggregation (MESH:D001791), fibrosis (MESH:D005355), tissue injury (MESH:D017695), bleeding (MESH:D006470), injury to (MESH:D014947), strokes (MESH:D020521), ischemic (MESH:D002545), inflammation (MESH:D007249), thrombosis (MESH:D013927), arrhythmias (MESH:D001145), VICs (MESH:D007984), SVD (MESH:D020914), myxomatous degeneration (MESH:D009410), TEHV (MESH:D006349), diabetes (MESH:D003920), fatigue (MESH:D005221), hypertension (MESH:D006973), calcification (MESH:D002114), thromboembolic (MESH:D013923), heart failure (MESH:D006333), toxicity (MESH:D064420), stenosis (MESH:D003251)
- **Chemicals:** GDL (MESH:C010730), PLA (MESH:C033616), nitinol (MESH:C013616), Valine (MESH:D014633), PGS (MESH:C469892), PVA (MESH:D011142), GAG (MESH:D006025), PCL (MESH:C016240), NO (MESH:D009569), polysulfone (MESH:C017662), Polymers (MESH:D011108), ROS (MESH:D017382), PEGDA (MESH:C437167), ChsMA (-), NiTi (MESH:C040654), ester (MESH:D004952), BP (MESH:D004164), PU (MESH:D011140), fucoidan (MESH:C007789), poly(ethylene terephthalate) (MESH:D011093), Cu (MESH:D003300), Sugar (MESH:D000073893), CaCO3 (MESH:D002119), poly(acrylonitrile) (MESH:C010504), CaCl2 (MESH:D002122), silica (MESH:D012822), polyhydroxyalkanoates (MESH:D054813), water (MESH:D014867), PGA (MESH:D011100), HA (MESH:D006820), Simvastatin (MESH:D019821), metal (MESH:D008670), alginate (MESH:D000464), CS (MESH:D002809), Heparin (MESH:D006493), chitosan (MESH:D048271), polyester (MESH:D011091), DAPI (MESH:C007293), RGD (MESH:C047981), glutaraldehyde (MESH:D005976)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** A7r5 — Rattus norvegicus (Rat), Spontaneously immortalized cell line (CVCL_0137)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13023917/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13023917/full.md

## References

125 references — full list in the complete paper: https://tomesphere.com/paper/PMC13023917/full.md

---
Source: https://tomesphere.com/paper/PMC13023917